Experiment 1076645
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | BEDIKIAN,AY: VALDI-VIESO,M: MAROUN,J: GUTTERMAN,JU: HERSH,EM: BODEY,GP:. (1980). EVALUATION OF VINDESINE AND MER IN COLORECTAL CANCER.. 46() |
| Amount utilized | |
| Compound isolated | |
| Disease | CLINICAL TRIAL IVOLVING 39 PATIENTS WITH ADVANCED COLORECTAL CANCER REFRACTORY TO 5-FU ALONE OR IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS. TUMOR REGRESSION OF MORE THAN 50% WAS SEEN IN 2 AND STABLE DISEASE IN 13 OF 33 PATIENTS EVALUABLE FOR RESPONSE PRIOR TREATMENT WITH VINCRISTINE DID NOT SEEM TO INFLUENCE RESPONSE TO VINDESINE. MEDIAN SURVIVAL TIME WAS FOUR MONTHS. THE MAJOR TOXIC EFFECT OF VINDESINE WAS PERIPHERAL NEUROPATHY,WHICH OCCURRED IN 35% OF PATIENTS WHO RECEIVED TWO OR MORE COURSES OF TREATMENT ADMINISTRATION OF A METHANOLIC EXTRACT RESIDUE OF BCG IV TO 20 OF 39 PATIENTS RECEIVING VINDESINE DID NOT SEEM TO SIGNIFICANTLY INFLUENCE THE RESPONSE RATE TO VINDESINE OR THE SURVIVAL OF PATIENTS. HOWEVER,IT APPEARED TO AMELIORATE THE MYELOSUPPRESSION CAUSED BY VINDESINE |
| Dose amount | 4.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |